CN106421039A - 一种防治雾霾引起的病症的中药组合物、其制备方法和含其的口罩 - Google Patents
一种防治雾霾引起的病症的中药组合物、其制备方法和含其的口罩 Download PDFInfo
- Publication number
- CN106421039A CN106421039A CN201610891372.7A CN201610891372A CN106421039A CN 106421039 A CN106421039 A CN 106421039A CN 201610891372 A CN201610891372 A CN 201610891372A CN 106421039 A CN106421039 A CN 106421039A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- preparation
- parts
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 195
- 239000000203 mixture Substances 0.000 title claims abstract description 129
- 238000002360 preparation method Methods 0.000 title claims abstract description 80
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 62
- 201000010099 disease Diseases 0.000 title claims abstract description 57
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 91
- 239000000284 extract Substances 0.000 claims abstract description 57
- 239000002994 raw material Substances 0.000 claims abstract description 48
- 239000000341 volatile oil Substances 0.000 claims abstract description 27
- 229940079593 drug Drugs 0.000 claims description 38
- 239000003921 oil Substances 0.000 claims description 34
- 239000002671 adjuvant Substances 0.000 claims description 25
- 238000007803 cold maceration Methods 0.000 claims description 19
- 238000007598 dipping method Methods 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 17
- 239000002552 dosage form Substances 0.000 claims description 16
- 241000628997 Flos Species 0.000 claims description 14
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 claims description 12
- 239000012153 distilled water Substances 0.000 claims description 8
- 241001506047 Tremella Species 0.000 claims description 7
- 150000004676 glycans Chemical class 0.000 claims description 7
- 229920001282 polysaccharide Polymers 0.000 claims description 7
- 239000005017 polysaccharide Substances 0.000 claims description 7
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 6
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 6
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 6
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 6
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 6
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 6
- 239000000835 fiber Substances 0.000 claims description 6
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 6
- 229920002674 hyaluronan Polymers 0.000 claims description 6
- 229960003160 hyaluronic acid Drugs 0.000 claims description 6
- 238000004821 distillation Methods 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 206010011224 Cough Diseases 0.000 abstract description 43
- 230000000694 effects Effects 0.000 abstract description 42
- 206010036790 Productive cough Diseases 0.000 abstract description 16
- 208000011580 syndromic disease Diseases 0.000 abstract description 11
- 208000024794 sputum Diseases 0.000 abstract description 9
- 210000003802 sputum Anatomy 0.000 abstract description 9
- 238000003780 insertion Methods 0.000 abstract description 2
- 230000037431 insertion Effects 0.000 abstract description 2
- 235000006679 Mentha X verticillata Nutrition 0.000 abstract 1
- 235000002899 Mentha suaveolens Nutrition 0.000 abstract 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 description 40
- 210000003800 pharynx Anatomy 0.000 description 25
- 238000010992 reflux Methods 0.000 description 23
- 206010062717 Increased upper airway secretion Diseases 0.000 description 21
- 208000026435 phlegm Diseases 0.000 description 21
- 238000011109 contamination Methods 0.000 description 19
- 241000700159 Rattus Species 0.000 description 17
- 239000013641 positive control Substances 0.000 description 15
- 210000002345 respiratory system Anatomy 0.000 description 13
- 230000001717 pathogenic effect Effects 0.000 description 12
- 230000002685 pulmonary effect Effects 0.000 description 11
- 230000000954 anitussive effect Effects 0.000 description 10
- 230000003110 anti-inflammatory effect Effects 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 10
- 239000012530 fluid Substances 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 230000009471 action Effects 0.000 description 9
- 238000009835 boiling Methods 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 210000003437 trachea Anatomy 0.000 description 9
- 102000013563 Acid Phosphatase Human genes 0.000 description 8
- 108010051457 Acid Phosphatase Proteins 0.000 description 8
- 208000003251 Pruritus Diseases 0.000 description 8
- 239000003463 adsorbent Substances 0.000 description 8
- 208000006673 asthma Diseases 0.000 description 8
- 230000003419 expectorant effect Effects 0.000 description 8
- 239000007789 gas Substances 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 230000007803 itching Effects 0.000 description 8
- 210000003097 mucus Anatomy 0.000 description 8
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 7
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 7
- 208000008454 Hyperhidrosis Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 210000000038 chest Anatomy 0.000 description 7
- 210000004081 cilia Anatomy 0.000 description 7
- 238000009833 condensation Methods 0.000 description 7
- 230000005494 condensation Effects 0.000 description 7
- 201000009240 nasopharyngitis Diseases 0.000 description 7
- 210000001331 nose Anatomy 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 7
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- 206010037660 Pyrexia Diseases 0.000 description 6
- 239000003172 expectorant agent Substances 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000003595 mist Substances 0.000 description 6
- 210000000214 mouth Anatomy 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 241000193830 Bacillus <bacterium> Species 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 5
- 208000013219 diaphoresis Diseases 0.000 description 5
- 208000001848 dysentery Diseases 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000000867 larynx Anatomy 0.000 description 5
- 210000004877 mucosa Anatomy 0.000 description 5
- 210000003928 nasal cavity Anatomy 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 230000035807 sensation Effects 0.000 description 5
- 235000019615 sensations Nutrition 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 4
- 206010039101 Rhinorrhoea Diseases 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 229940124584 antitussives Drugs 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 208000010753 nasal discharge Diseases 0.000 description 4
- 238000003809 water extraction Methods 0.000 description 4
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 3
- 206010063659 Aversion Diseases 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 3
- 241000721047 Danaus plexippus Species 0.000 description 3
- 206010028748 Nasal obstruction Diseases 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 210000002588 alveolar type II cell Anatomy 0.000 description 3
- 230000003266 anti-allergic effect Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000000621 bronchi Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 229960002179 ephedrine Drugs 0.000 description 3
- 239000000469 ethanolic extract Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 238000007667 floating Methods 0.000 description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 229940041616 menthol Drugs 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- 244000056139 Brassica cretica Species 0.000 description 2
- 235000003351 Brassica cretica Nutrition 0.000 description 2
- 235000003343 Brassica rupestris Nutrition 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 235000007516 Chrysanthemum Nutrition 0.000 description 2
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 2
- 241000186216 Corynebacterium Species 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000018569 Respiratory Tract disease Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 235000001667 Vitex agnus castus Nutrition 0.000 description 2
- 244000063464 Vitex agnus-castus Species 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 2
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 206010013023 diphtheria Diseases 0.000 description 2
- 208000028659 discharge Diseases 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 239000001685 glycyrrhizic acid Substances 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- 210000002175 goblet cell Anatomy 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 229960001660 histamine phosphate Drugs 0.000 description 2
- ZHIBQGJKHVBLJJ-UHFFFAOYSA-N histamine phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.NCCC1=CNC=N1 ZHIBQGJKHVBLJJ-UHFFFAOYSA-N 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 235000010460 mustard Nutrition 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000001533 respiratory mucosa Anatomy 0.000 description 2
- 239000004576 sand Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000004071 soot Substances 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 239000004577 thatch Substances 0.000 description 2
- 210000005090 tracheal smooth muscle Anatomy 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 1
- NZGWDASTMWDZIW-MRVPVSSYSA-N (+)-pulegone Chemical compound C[C@@H]1CCC(=C(C)C)C(=O)C1 NZGWDASTMWDZIW-MRVPVSSYSA-N 0.000 description 1
- WTARULDDTDQWMU-RKDXNWHRSA-N (+)-β-pinene Chemical compound C1[C@H]2C(C)(C)[C@@H]1CCC2=C WTARULDDTDQWMU-RKDXNWHRSA-N 0.000 description 1
- FMCGSUUBYTWNDP-ONGXEEELSA-N (1R,2S)-2-(dimethylamino)-1-phenyl-1-propanol Chemical compound CN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 FMCGSUUBYTWNDP-ONGXEEELSA-N 0.000 description 1
- VQQGPFFHGWNIGX-PPCHTBMASA-N (4as,6ar,6as,6br,8ar,10s,12ar,14bs)-10-[(2s,3r,4s,5s)-3-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-4,5-dihydroxyoxan-2-yl]oxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a, Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H](OC[C@H](O)[C@@H]2O)O[C@@H]2C([C@H]3[C@]([C@@H]4[C@@]([C@@]5(CC[C@]6(CCC(C)(C)C[C@H]6C5=CC4)C(O)=O)C)(C)CC3)(C)CC2)(C)C)O[C@H](CO)[C@@H](O)[C@@H]1O VQQGPFFHGWNIGX-PPCHTBMASA-N 0.000 description 1
- OQWKEEOHDMUXEO-UHFFFAOYSA-N (6)-shogaol Natural products CCCCCC=CC(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-UHFFFAOYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 208000035985 Body Odor Diseases 0.000 description 1
- 206010055000 Bromhidrosis Diseases 0.000 description 1
- 101100269850 Caenorhabditis elegans mask-1 gene Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010018092 Generalised oedema Diseases 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241001215120 Leptospirales Species 0.000 description 1
- 241000222065 Lycoperdon Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- 241001480037 Microsporum Species 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 102000001621 Mucoproteins Human genes 0.000 description 1
- 108010093825 Mucoproteins Proteins 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- FMCGSUUBYTWNDP-UHFFFAOYSA-N N-Methylephedrine Natural products CN(C)C(C)C(O)C1=CC=CC=C1 FMCGSUUBYTWNDP-UHFFFAOYSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 1
- 244000236458 Panicum colonum Species 0.000 description 1
- 235000015225 Panicum colonum Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 241000768494 Polymorphum Species 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- NZGWDASTMWDZIW-UHFFFAOYSA-N Pulegone Natural products CC1CCC(=C(C)C)C(=O)C1 NZGWDASTMWDZIW-UHFFFAOYSA-N 0.000 description 1
- VQQGPFFHGWNIGX-UHFFFAOYSA-N Raddeanin A Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(OCC(O)C2O)OC2C(C3C(C4C(C5(CCC6(CCC(C)(C)CC6C5=CC4)C(O)=O)C)(C)CC3)(C)CC2)(C)C)OC(CO)C(O)C1O VQQGPFFHGWNIGX-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 241000605008 Spirillum Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 108010078184 Trefoil Factor-3 Proteins 0.000 description 1
- 102000014456 Trefoil Factor-3 Human genes 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- OQWKEEOHDMUXEO-BQYQJAHWSA-N [6]-Shogaol Chemical compound CCCCC\C=C\C(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-BQYQJAHWSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- JUGOREOARAHOCO-UHFFFAOYSA-M acetylcholine chloride Chemical compound [Cl-].CC(=O)OCC[N+](C)(C)C JUGOREOARAHOCO-UHFFFAOYSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- VYBREYKSZAROCT-UHFFFAOYSA-N alpha-myrcene Natural products CC(=C)CCCC(=C)C=C VYBREYKSZAROCT-UHFFFAOYSA-N 0.000 description 1
- USMNOWBWPHYOEA-UHFFFAOYSA-N alpha-thujone Natural products CC1C(=O)CC2(C(C)C)C1C2 USMNOWBWPHYOEA-UHFFFAOYSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002804 anti-anaphylactic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001716 anti-fugal effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002223 anti-pathogen Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 1
- 229960003321 baicalin Drugs 0.000 description 1
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229930006722 beta-pinene Natural products 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000000739 chaotic effect Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000003958 fumigation Methods 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000004704 glottis Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000002440 industrial waste Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 239000011229 interlayer Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930007503 menthone Natural products 0.000 description 1
- 229960002221 methylephedrine Drugs 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000010553 multiple abscesses Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229930007459 p-menth-8-en-3-one Natural products 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- SBNFWQZLDJGRLK-UHFFFAOYSA-N phenothrin Chemical compound CC1(C)C(C=C(C)C)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 SBNFWQZLDJGRLK-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229950004354 phosphorylcholine Drugs 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229960003908 pseudoephedrine Drugs 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 210000001034 respiratory center Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000012154 short term therapy Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000008700 sympathetic activation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229930006978 terpinene Natural products 0.000 description 1
- 150000003507 terpinene derivatives Chemical class 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 201000009642 tinea barbae Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000000283 vasomotion Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- WTARULDDTDQWMU-UHFFFAOYSA-N β-pinene Chemical compound C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A41—WEARING APPAREL
- A41D—OUTERWEAR; PROTECTIVE GARMENTS; ACCESSORIES
- A41D13/00—Professional, industrial or sporting protective garments, e.g. surgeons' gowns or garments protecting against blows or punches
- A41D13/05—Professional, industrial or sporting protective garments, e.g. surgeons' gowns or garments protecting against blows or punches protecting only a particular body part
- A41D13/11—Protective face masks, e.g. for surgical use, or for use in foul atmospheres
- A41D13/1192—Protective face masks, e.g. for surgical use, or for use in foul atmospheres with antimicrobial agent
-
- A—HUMAN NECESSITIES
- A41—WEARING APPAREL
- A41D—OUTERWEAR; PROTECTIVE GARMENTS; ACCESSORIES
- A41D31/00—Materials specially adapted for outerwear
- A41D31/04—Materials specially adapted for outerwear characterised by special function or use
- A41D31/30—Antimicrobial, e.g. antibacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/538—Schizonepeta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9064—Amomum, e.g. round cardamom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pulmonology (AREA)
- Textile Engineering (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明属于中药领域,具体涉及一种防治雾霾引起的病症的中药组合物、其制备方法和含其的口罩,包括以下重量份数的原料组分1~30份的桔梗、0.5~15份的白前、0.1~10份的甘草、0.5~15份的陈皮、0.1~10份的薄荷和0.5~15份的荆芥。其制备方法包括以下步骤:水提取物的制备、药物挥发油的制备和制备中药组合物。本发明基于中医理论筛选有效方药,合理配伍得到中药组合物,使本发明的中药组合物及含其的口罩具有清霾润燥、宣肺、化痰、止咳的功效。将中药组合物制备成片状,在现有口罩的基础上添加药物插片,使口罩在佩戴时具有清霾、润燥、宣肺止咳化痰作用,有效缓解“雾霾综合征”。
Description
技术领域
本发明属于保健品技术领域,具体涉及一种防治雾霾引起的病症的中药组合物、其制备方法和含其的口罩。
背景技术
雾霾是雾和霾的组合词,显然雾和霾是两种不同的天气现象,世界气象组织以及中国观测规范对此也都有明确规定。雾是指由大量悬浮在近地面空气中的微小水滴或冰晶组成的、能见度降低到1千米以内的自然现象。而在中国气象局的《地面气象观测规范》中,灰霾天气被这样定义:“大量极微细的干性尘粒、烟粒等(气象学上称为气溶胶颗粒)均匀悬浮于空中,使空气混浊、视野模糊并导致能见度恶化,当水平能见度低于10.0km、相对湿度小于80%时,排除降水、扬沙、浮尘、烟雾、吹雪、雪暴、沙尘暴等天气现象造成视程障碍空气普遍混浊现象。”霾使得远处光亮物略微带黄、红色,使黑暗物微带蓝色,以上即为雾霾的气象学定义。
“雾霾”虽然在中医古籍中并无记载,但根据中医理论对病因的认识,“雾霾”应属于外感邪气,但此邪气不同于中医外感病因中的“六淫”,即风邪、寒邪、暑邪、湿邪、燥邪、火(热)邪等,也不同于疫气。城市雾霾是工业废气、汽车尾气、空气灰尘、空气细菌和病毒等污染物附着于水滴形成的细小颗粒物,此邪气从口鼻而入,易引发鼻干、咽干、咽痒、咽喉异物感等;肺为华盖,上通鼻窍,故继而犯肺,使肺失宣降,肺气上逆则为咳嗽、咳痰。喉为肺之门户,鼻为肺之外窍,雾霾所引发的鼻干、咽干、咽痒、咽喉异物感、咳嗽、咳痰等“雾霾综合征”均为肺系病症。
为了应对雾霾天气,保护好自身健康,现有技术中出现了大量用于治疗雾霾所引起呼吸道疾病的中药的技术方案,其剂型多为口服制剂,仅适合短期治疗食用。同时为了方便大众使用,有效防治雾霾所引起的相关病症,现有技术中出现了带有中药组合物的口罩,以有效隔绝雾霾,并针对咽喉、口鼻起到预防呼吸道疾病的作用。具体例如申请公布号为CN103238954A的发明专利公开了一种雾霾天气发生时保护人们呼吸道肺部免遭伤害的中药口罩,当雾霾天气沙尘暴天气发生时,佩戴该中药口罩能够有效阻挡空气中的极细微的尘粒、烟粒、浮尘、沙尘暴扬沙及各种其它有害污染物进入人们的呼吸道及肺部,保护人们呼吸道及肺部免遭伤害,口罩芯经过中草药紫苑、百部、款冬花三种中药组药治疗呼吸系统疾病的熬制好的中药汤剂浸泡过。佩戴该中药口罩的人们能够呼吸到经口罩芯过滤的湿润的洁净空气,及淡淡的三种中药散发出对身体有益的中药气味,感觉到呼吸道及肺部很舒服,该中药口罩对人们的呼吸道及肺部起到了很好的保护和消炎润肺的作用。但该口罩内的中药原料组分配伍较为单一,针对防治雾霾引起的病症功效不明显,且佩戴时的中药气味保留时间短,不能连续几天持续使用,增加了使用者的使用成本。
由此可见,能否基于现有技术中的不足,提供一种防治雾霾引起的病症的中药组合物和含其的口罩,使其具有各原料成分配伍合理,具有清霾、润燥、宣肺止咳化痰作用的中药药性,有效缓解“雾霾综合征”,同时制备的中药组合物放置于口罩中,在佩戴时能够持久保持中药气味,使佩戴者使用更持久,成为本领域技术人员亟待解决的技术难题。
发明内容
本发明为了解决上述技术问题,提供一种防治雾霾引起的病症的中药组合物、其制备方法和含其的口罩,有效针对雾霾所引发的鼻干、咽干、咽痒、咽喉异物感、咳嗽、咳痰等“雾霾综合征”起到防治的作用,且本发明所提供的口罩长期使用效果仍较佳。
为了达到上述技术效果,本发明包括以下技术方案:
一种防治雾霾引起的病症的中药组合物,包括以下重量份数的原料组分:1~30份的桔梗、0.5~15份的白前、0.1~10份的甘草、0.5~15份的陈皮、0.1~10份的薄荷和0.5~15份的荆芥。
桔梗有免疫调节、抗炎、祛痰、保肝、降血脂、抗氧化等方而的药理作用。临床上多用于咳嗽痰多,胸闷不畅,咽痛,声哑,肺痈吐脓,疮疡脓成不溃等症。其挥发油中有机酸和酯类化合物含量较高,不饱和化合物含量较高。桔梗水提物可对特异性、非特异性免疫应答起到增强的作用。
现有技术中有证实白前5g·每千克醇提物及醚提物给小鼠灌胃(ig),对浓氨水诱发的小鼠咳嗽有明显的镇咳和祛痰作用,表明白前对咳、痰、喘症状有良好改善作用。
甘草及其提取物具有抗菌、抗病毒、抗炎、抗癌、抗氧化等多种活性,高雪岩等也证明甘草对消化系统、呼吸系统、神经系统、内分泌系统等均具有调节和保护活性。张志峰等采用小鼠气管段酚红法测得甘草水提取物(液),高、中、低剂量组及阳性对照组小鼠气管的酚红排泌量均增加,甘草酸粉也可增加气管的酚红排泌量。表明甘草提取物和甘草酸粉具有明显的祛痰作用。
陈皮挥发油:柠檬烯、旅烯、松油烯、月桂烯为陈皮挥发油主要组分挥发油能松弛气管平滑肌、阻断或解除氯化乙酞胆碱或磷酸组胺所致的气管平滑肌的收缩痉挛、对豚鼠药物性哮喘具保护作用、能解除肠肌的收缩痉挛状态及抗过敏作用此外,陈皮挥发油治疗大鼠实验性结肠炎有效,可能与免疫调节有关。
薄荷的主要有效成分是挥发油类。现代研究表明,薄荷具有抗肿瘤,促进透皮吸收、抗炎镇痛、抗真菌、抗病毒的作用,并对中枢神经系统、消化系统、生殖系统、呼吸系统等均有一定作用。其对对呼吸系统的作用显著:薄荷醇的刺激作用导致气管产生新的分泌,使稠厚的黏液易于排出。薄荷醇用于支气管炎时,能减少呼吸道的泡沫痰,使有效通气腔道增大,而表现祛痰作用。薄荷有镇咳作用。家兔吸入薄荷醇蒸气能使呼吸道黏膜分泌增加,使粘液稀释而表现祛痰作用。
荆芥作为一味常用的解表药,化学研究表明挥发油为其主要有效部位群之一,其中又以薄荷酮和胡薄荷酮为主要成分。药理学研究己表明荆芥挥发油是其抗炎抗过敏的主要物质基础。
陈皮理气化痰止咳;荆芥、桔梗疏风透表,宣利肺气;甘草调和诸药,祛痰止咳,与桔梗相配又可清利咽喉。全方共奏疏表、润肺、宣肺、止咳、化痰,加之口罩的清霾作用,可以有效的防治雾霾所引起的各种病症。
本发明将上述各原料成分合理配伍,遵循君臣佐使原则,桔梗归肺经,功在宣肺利咽祛痰。桔梗之用,惟其上入肺经,肺为主气之脏,故能使诸气下降,肺气上逆发为咳嗽,桔梗入肺经,降肺气,以为君药。白前归肺经,降气消痰止咳。《本草纲目》云,白前降气下痰,故为臣药。与桔梗同用,一升一降,使气机运转,复肺气之宣降,增强君药的止咳化痰之力。荆芥可疏风解表,除在表之邪;陈皮理气健脾,燥湿化痰;薄荷辛凉解表,辛能发散,凉能清利,气清郁香窜,均为佐药。甘草缓急和中,亦能祛痰止咳,调和诸药,以之为使。
使得配伍的各原料成分具有协同作用,清霾润燥、宣肺、化痰、止咳的功效较佳。
进一步优选地的,包括以下重量份数的原料组分:2~8份的桔梗、1~5份的白前、1~5份的甘草、1~5份的陈皮、1~4份的薄荷和1~5份的荆芥。
经进一步筛选得到上述优选的各原料含量值,使得中药组合物清霾润燥、宣肺、化痰、止咳效果更佳。
进一步的,还包括以下重量份数的原料组分:重量份数为0.1~10份的紫苏叶、0.1~10份的炙麻黄、0.1~10份的干姜、0.1~10份的桂枝、0.1~10份的桑叶、0.1~10份的菊花、0.1~10份的黄芩、0.1~10份的牛蒡子、0.1~10份的苍术、0.1~10份的半夏和0.1~10份的草果中的一种或几种。
进一步的,所述中药组合物还包括重量份数为0.1~10份的紫苏叶和0.1~10份的炙麻黄;其针对风寒症状缓解效果更佳,同时能够有效清霾,缓解风寒症状。
进一步优选的,所述中药组合物还包括重量份数为0.1~10份的紫苏叶、0.1~10份的炙麻黄、0.1~10份的干姜和0.1~10份的桂枝。其针对重症风寒症状效果更佳,同时能够有效清霾,缓解风寒症状。
上述两种中药组合物其针对风寒症状效果更佳,风寒咳嗽声重,气急,咽痒,咳痰稀薄色白,常伴鼻塞,流清涕,头痛,肢体酸楚,或见恶寒发热,无汗。舌苔薄白。风热咳嗽频剧,声粗或咳声嘶哑,喉燥咽痛,咳痰不爽,痰粘稠或黄,咳时汗出,常伴鼻流黄涕,口渴,头痛,身楚,或恶风,身热。舌苔薄黄。雾湿咳声重浊,痰多,痰黏腻或稠厚成块,色白或带灰色,胸闷脘痞,呕恶食少,体倦,大便时溏,舌苔白腻。在雾霾天气中,风寒患者鼻塞、喉燥咽痛等症状会加剧,因此添加上述组分的原料,针对风寒患者缓解效果更佳,同时有效清霾。具体如下:
紫苏叶:解表散寒,行气和胃。有文献表明,紫苏治疗慢性气管炎:取干苏叶与少量干姜(10:1),制成25%苏叶药液。每日早晚各服一次,每次100毫升,10天为一疗程。两疗程间隔3天。观察552例,经四个疗程后近期控制62例(11.2%,显效150例(27.2%),好转213例(38.6%,无效127例(23%)。对单纯型(434例)和喘息型疗效相似。对咳、喘、痰三症均有一定疗效。用药后多数患者反映食欲增加,部分患者睡眠较前安静,心跳减轻,个别病例出现利尿作用,浮肿消退。仅个别患者出现口干、唾液减少等副反应,一般均较轻微,为时短暂,不须处理,可自行消失。
桂枝:发汗解肌,温通经脉,助阳化气,平冲降气。桂枝辛温,善祛风寒,能治感冒风寒、发热恶寒,不论有汗、无汗都可应用。有研究表明,其具有:1.抗菌作用:桂枝醇提物在体外能抑制大肠杆菌、枯草杆菌及金黄色葡萄球菌,有效浓度为25mg/ml或以下;对白色葡萄球菌、志贺氏痢疾杆菌、伤寒和副伤寒甲杆菌、肺炎球菌、产气杆菌、变形杆菌、炭疽杆菌、肠炎沙门氏菌、霍乱弧菌等亦有抑制作用(平板挖洞法)。2.抗病毒作用:用人胚肾原代单层上皮细胞组织培养,桂枝煎剂(1∶20)对流感亚洲甲型京科68-l株和孤儿病毒(ECHO11)有抑制作用。在鸡胚上,对流感病毒有抑制作用,以70%醇浸剂作用较好。
麻黄:发汗散寒,宣肺平喘,利水消肿。用于风寒感冒,胸闷喘咳,风水浮肿;支气管哮喘。麻黄性温辛散,能发汗散寒而解表,又可散风透疹。用治外感风寒所引起的发热恶寒、无汗等症,常与桂枝相须为用,有发汗解表的作用。麻黄能宣畅肺气而止咳平喘,故临床往往用治外邪侵袭、肺气不畅所致的喉痒咳嗽、咯痰不爽或咳嗽紧迫、胸闷、气喘等症。其作用有:1.对支气管平滑肌的松驰作用较肾上腺素弱而持久。离体兔肺支气管灌注,低浓度麻黄碱及伪麻黄碱均引起支气管扩张。左旋麻黄碱和右旋伪麻黄碱能缓解由组胺或乙酰胆碱所致犬呼吸道阻力增加,甲基麻黄碱也能舒张支气管平滑肌。2.麻黄挥发油乳剂对人工发热的兔有解热作用,麻黄挥发油及萜品烯醇对正常小鼠体温有降温作用,以萜品烯醇作用更为明显,二者对正常及发热猫未见引起发汗。麻黄碱及麻黄总生物碱对人不能诱发出汗,当人暴露于高温1.5-2小时后,给与麻黄碱50-60mg,出汗量比未暴露于高温者快而多,提示对人有中等度发汗作用,这种作用可能是由于麻黄阻碍了汗腺导管对钠的重吸收而导致汗腺分泌增加。D-伪麻黄碱口服50mg,可使实验动物血管通透性降低,而呈抗炎作用,这也有助于解热。3.麻黄水提物口服或腹腔注射有镇咳作用。用组胺气雾致喘法试验,小鼠腹腔注射麻黄挥发油0.1ml/kg具有平喘作用,麻黄挥发油组小鼠致喘时间为7.2±2.1分钟,而生理盐水组为2.2±0.7分钟(P<0.05)。酚红法试验发现给小鼠灌胃麻黄挥发油0.4ml/kg具有促进气管排泌酚红的作用。
干姜:干姜温中散寒,回阳通脉,燥湿消痰。参考生姜的作用:其有效成分姜烯酚具有兴奋迷走神经及抑制心脏引起的降压作用、末梢血管收缩作用、交感神经兴奋作用等部分地参与而引起升压作用。正常人口嚼生姜1g咽下,可使血压上升。其醇提物对血管运动中枢及呼吸中枢有兴奋作用。对心脏也有直接兴奋作用,还能使血管扩张,促进血液循环。
适用症:头痛,鼻塞,流清鼻涕,怕风,舌淡红苔白,脉浮紧为风寒束表、肺卫失宣的表现。
进一步的,所述中药组合物还包括重量份数为0.1~10份的桑叶和0.1~10份的菊花。其针对风热型流涕、咳嗽的病症缓解效果更佳,同时能够有效清霾,缓解风热型感冒时咳嗽、流涕症状。
进一步优选的,所述中药组合物还包括重量份数为0.1~10份的桑叶、0.1~10份的菊花、0.1~10份的黄芩和0.1~10份的牛蒡子。其针对重症风热型感冒症状效果更佳,同时能够有效清霾,缓解风热型感冒症状。
桑叶:疏散风热,清肺润燥,清肝明目。桑叶善于散风热而泄肺热,对外感风热、头痛、咳嗽等。其药理实验表明:抗菌作用鲜桑叶煎剂体外实验,对金黄色葡萄球菌、乙型溶血性链球菌、白喉杆菌和炭疸杆菌均有较强的抗菌作用,对大肠杆菌、伤寒杆菌、痢疾杆菌、绿脓杆菌也有一定的抗菌作用。煎剂还有杀钩端螺旋体的作用。
菊花:散风清热,平肝明目。其药理作用有:①抗病原体作用:菊花在体外对革兰氏阳性细菌(金黄色葡萄球菌及β-溶血性链球菌)、人型结核杆菌有某些抑制作用。其水浸剂(1:4)对某些常见皮肤致病性真菌亦有些抑制作用。高浓度在体外还有抗病毒(PB8株)及抗螺旋体作用。②增强毛细血管抵抗力。菊花提取物从鼠腹腔注射,可使皮内注射组织胺之局部台盼蓝之扩散较小,显示其能抑制毛细血管的通透性而有抗炎作用。其提取物10毫克相当芦丁2.5毫克之效力。
黄芩:清热燥湿,泻火解毒,止血,安胎。可用于湿温、暑温胸闷呕恶,湿热痞满,泻痢,黄疸,肺热咳嗽。其药理作用包括:①抗炎抗变态反应:黄芩甙、黄芩甙元对豚鼠寓体气管过敏性收缩及整体动物过敏性气喘,均有缓解作用,并与麻黄碱表现协同。②抗微生物作用:黄芩有较广的抗菌谱,在试管内对痢疾杆菌、白喉杆菌、绿脓杆菌、葡萄球菌、链球菌、肺炎双球菌以及脑膜炎球菌等均有抑制作用,煎剂作喉头喷雾,对脑膜炎带菌者亦有效,即使对青霉素等抗菌素已产生抗药性的金黄色葡萄球菌,对黄芩仍属敏感。试管内对人型结核杆菌的抑制作用,报告不一致,煎剂对小白鼠实验性结核病有效,但对豚鼠则无效。试管内对流感病毒PR株有抑制作用,鼠痞染病毒后,能使之减轻肺部损伤和延长存活日期。
牛蒡子:疏散风热;清热解毒透疹;宣肺利咽散肿。药理实验表明:牛蒡子煎剂对肺炎双球菌有显著抗菌作用。水浸剂对多种致病性皮肤真菌有不同程度的抑制作用。牛蒡子有解热、利尿、降低血糖、抗肿瘤作用。适用于咽喉肿痛,流黄鼻涕,咳吐黄痰,舌红苔薄,脉弦数等风热犯肺的患者。
进一步的,所述中药组合物还包括重量份数为0.1~10份的苍术。该中药组合物针对雾湿型咽喉症状缓解效果更佳,同时能够有效清霾。
进一步优选的,所述中药组合物还包括重量份数为0.1~10份的苍术、0.1~10份的半夏和0.1~10份的草果。该中药组合物针对重症雾湿型咽喉症状缓解效果更佳,同时能够有效清霾。
苍术:燥湿健脾,祛风散寒。李杲:"除湿发汗,健胃安脾,治痿要药。"《本草正义》:苍术……夏秋之交,暑湿交蒸,湿温病寒热头胀如裹,或胸痞呕恶,皆须茅术、藿香、佩兰叶等香燥醒脾,其应如响。而脾家郁湿,或为膜胀,或为肿满,或为泻泄疟痢,或下流而足重跗肿,或积滞而二便不利,及湿热郁蒸,发为疮疡流注,或寒湿互结,发为阴疽酸痛,但有舌浊不渴见证,茅术一味,最为必需之品。是合内外各病,皆有大用者。
半夏:燥湿化痰,降逆止呕,消痞散结。其药理研究表明:其具有镇咳作用:生半夏、姜半夏、姜浸半夏和明矾半夏的煎剂,0.6-1g/kgig或iv,对猫碘液注入胸腔或电刺激喉上神经所致的咳嗽有明显的镇咳作用,且可维持5小时以上。0.6g/kg的镇咳作用接近于可待因lmg/kg的作用。
草果:燥湿温中,除痰截疟。其药理作用包括:
①镇咳祛痰作用:本品所含的a-和β-蒎烯有镇咳祛痰作用。1,8-桉油素有镇痛、解热、平喘等作用。②抗炎、抗菌作用:B-蒎烯有较强的抗炎作用,并有抗真菌作用。香叶醇有抗细菌和真菌作用,对发须癣菌和奥杜安氏小孢子菌的最低抑菌浓度为0.39mg/ml。
适用于湿气困脾,大便稀溏,食少倦怠,不思饮食的患者。
本发明中药组合物进一步合理配伍上述原料组分,进一步增加中药组合物的功效,使其针对鼻干、咽干、咽痒、咽喉均有缓解功效。
进一步的,所述的中药组合物的剂型为吸入剂,所述吸入剂还包括辅料。
本发明中药组合物中合理配伍有效成分为挥发油的原料组分,制备成的吸入剂能够通过人的正常吸入起到防治“雾霾综合征”的功效,其中雾霾所引发的鼻干、咽干、咽痒、咽喉异物感、咳嗽、咳痰等均为“雾霾综合征”。
进一步的,所述辅料包括以下重量百分数的原料组分:0.01~0.5%的透明质酸、0.01~0.5%的银耳多糖、0.1~1%的三甲基甘氨酸、0.01~0.5%的羟乙基纤维和0.01~0.5%的对羟基苯甲酸乙酯中的一种或几种,余量为无菌蒸馏水。
一种上述防治雾霾引起的病症的中药组合物的制备方法,包括以下步骤:
步骤一:水提取物的制备:取白前、桔梗和甘草置于水中草采用冷浸法或热浸法制备水提取物;
步骤二:药物挥发油的制备:取陈皮、荆芥和薄荷,采用蒸馏萃取方式得到相应的药物挥发油;
步骤三:制备中药组合物:取步骤一制备的水提取物和步骤二制备的药物混发油混合均匀,。
另外针对本发明中药组合物中的白前、桔梗、甘草有效成分为水提取物(液),故采取水提取的方式。以桔梗为例。麻醉犬、猫灌服桔梗水煎剂可使呼吸道粘液分泌量显著增加,产生祛痰作用。桔梗水煎剂能通过增加肺部血管活性肠肽(VIP)、肠三叶因子(TFF3)的表达量发挥祛痰镇咳作用。桔梗水提物对机械刺激咳嗽动物模型的镇咳效果明显。其中,桔梗皂甙D和D3(单体皂甙)增加大鼠和小鼠呼吸道黏蛋白的释放,增加支气管腺体分泌,发挥祛痰作用。针对本发明中药组合物中的陈皮、荆芥、薄荷有效成分为挥发油,故采取蒸馏萃取的方式。以陈皮为例,陈皮挥发油能阻断氯化乙酰胆碱、磷酸组胺引起的支气管平滑肌收缩痉挛,具有平喘、镇咳和抗变应性炎症的作用。陈皮所含的挥发油还可刺激呼吸道黏膜,促使分泌增多、痰液稀释、利于排出。
进一步的,所述步骤一中水提取物的原料还包括炙麻黄、干姜、桑叶、菊花和黄芩中的一种以上。
进一步的,所述步骤二药物挥发油的原料还包括紫苏叶、桂枝、牛蒡子、苍术、半夏和草果中的一种以上。
进一步的,所述的中药组合物的剂型为吸入剂,所述吸入剂还包括辅料,取制备的中药组合物与辅料混合均匀,所述辅料包括以下重量百分数的原料组分:0.01~0.5%的透明质酸、0.01~0.5%的银耳多糖、0.1~1%的三甲基甘氨酸、0.01~0.5%的羟乙基纤维和0.01~0.5%的对羟基苯甲酸乙酯中的一种或几种,余量为无菌蒸馏水。
一种含有中药组合物的口罩,所述的中药组合物为上述的防治雾霾引起的病症的中药组合物。
本发明提供的含有中药组合物的口罩,合理配伍中药组合物的各原料成分,将中药组合物制备成片状,放置于口罩夹层中,使其置于口鼻接触位置。以达到阻挡有害的气体进出佩戴者口鼻的作用,代替饮用中药的防治方式,采用佩戴方式更加便捷舒适,乐于接受。
进一步优选的,所述的口罩为加湿口罩或空气过滤式口罩。
采用上述技术方案,包括以下有益效果:本发明提供的一种防治雾霾引起的病症的中药组合物、其制备方法和含其的口罩,基于中医理论筛选有效方药,合理配伍得到中药组合物,使本发明的中药组合物及含其的口罩具有清霾润燥、宣肺、化痰、止咳的功效。将中药组合物制备成片状,在现有口罩的基础上添加药物插片,使口罩在佩戴时具有清霾、润燥、宣肺止咳化痰作用,有效缓解“雾霾综合征”。
具体实施方式
下面通过具体的实施例对本发明做进一步的详细描述。
实施例一:一种防治雾霾引起的病症的中药组合物,包括以下重量份数的原料组分:1份的桔梗、15份的白前、0.1份的甘草、15份的陈皮、0.1份的薄荷和15份的荆芥。
实施例二:一种防治雾霾引起的病症的中药组合物,包括以下重量份数的原料组分:2份的桔梗、5份的白前、1份的甘草、5份的陈皮、1份的薄荷和5份的荆芥。
一种防治雾霾引起的病症的中药组合物的制备方法,其特征在于,包括以下步骤:
步骤一:水提取物的制备:取白前、桔梗和甘草采用冷浸法或热浸法制备水提取物;
步骤二:药物挥发油的制备:取陈皮、荆芥和薄荷,采用蒸馏萃取方法得到相应的药物挥发油;
步骤三:制备中药组合物:取步骤一制备的水提取物和步骤二制备的药物混发油经离心机充分搅拌得到药物混合液,得到中药组合物。
实施例三:一种防治雾霾引起的病症的中药组合物,其剂型为吸入剂,包括以下重量份数的原料组分:4份的桔梗、3份的白前、2份的甘草、3份的陈皮、2份的薄荷和3份的荆芥。
一种防治雾霾引起的病症的中药组合物的制备方法,其特征在于,包括以下步骤:
步骤一:水提取物的制备:取白前、桔梗和甘草采用冷浸法或热浸法制备水提取物;
冷浸法包括以下步骤:按上述重量份数称取原料组分,置于锥形瓶中,精密加水,密塞,冷浸,前6个小时内时时振摇,再静置18小时,用干燥滤器迅速滤过得到水提取物;
热浸法包括以下步骤:按上述重量份数称取原料组分,置于锥形瓶中,精密加水,密塞,称定重量,静置1小时后,连接回流冷凝管,加热至沸腾,并保持微沸1小时;放冷后,取下锥形瓶,密塞,再称定重量,用水补足减失的重量,摇匀,用干燥器滤过,精密量取滤液得到水提取物;
步骤二:药物挥发油的制备:取陈皮、荆芥和薄荷,加入硬质圆底烧瓶,在硬质圆底烧瓶上连接挥发油测定器和回流冷凝管,经回流冷凝,得到药物挥发油;
步骤三:制备中药组合物:取步骤一制备的水提取物和步骤二制备的药物混发油经离心机充分搅拌得到药物混合液,得到中药组合物。
实施例四:一种防治雾霾引起的病症的中药组合物,其剂型为吸入剂,包括以下重量份数的原料组分:4份的桔梗、3份的白前、2份的甘草、3份的陈皮、2份的薄荷、3份的荆芥、重量份数为0.1份的紫苏叶和10份的炙麻黄。
一种防治雾霾引起的病症的中药组合物的制备方法,其特征在于,包括以下步骤:
步骤一:水提取物的制备:取白前、桔梗、甘草和炙麻黄采用冷浸法或热浸法制备水提取物;
冷浸法包括以下步骤:按上述重量份数称取原料组分,置于锥形瓶中,精密加水,密塞,冷浸,前6个小时内时时振摇,再静置18小时,用干燥滤器迅速滤过得到水提取物;
热浸法包括以下步骤:按上述重量份数称取原料组分,置于锥形瓶中,精密加水,密塞,称定重量,静置1小时后,连接回流冷凝管,加热至沸腾,并保持微沸1小时。放冷后,取下锥形瓶,密塞,再称定重量,用水补足减失的重量,摇匀,用干燥器滤过,精密量取滤液得到水提取物;
步骤二:药物挥发油的制备:取陈皮、荆芥、薄荷、紫苏叶,加入硬质圆底烧瓶,在硬质圆底烧瓶上连接挥发油测定器和回流冷凝管,经回流冷凝,得到药物挥发油;
步骤三:制备中药组合物:取步骤一制备的水提取物和步骤二制备的药物混发油经离心机充分搅拌得到药物混合液,得到中药组合物。
实施例五:一种防治雾霾引起的病症的中药组合物,其剂型为吸入剂,包括以下重量份数的原料组分:4份的桔梗、3份的白前、2份的甘草、3份的陈皮、2份的薄荷、3份的荆芥、10份的紫苏叶、0.1份的炙麻黄、10份的干姜和0.1份的桂枝。
一种防治雾霾引起的病症的中药组合物的制备方法,其特征在于,包括以下步骤:
步骤一:水提取物的制备:取白前、桔梗、甘草、炙麻黄和干姜采用冷浸法或热浸法制备水提取物;
冷浸法包括以下步骤:按上述重量份数称取原料组分,置于锥形瓶中,精密加水,密塞,冷浸,前6个小时内时时振摇,再静置18小时,用干燥滤器迅速滤过得到水提取物;
热浸法包括以下步骤:按上述重量份数称取原料组分,置于锥形瓶中,精密加水,密塞,称定重量,静置1小时后,连接回流冷凝管,加热至沸腾,并保持微沸1小时。放冷后,取下锥形瓶,密塞,再称定重量,用水补足减失的重量,摇匀,用干燥器滤过,精密量取滤液得到水提取物;
步骤二:药物挥发油的制备:取陈皮、荆芥、薄荷、紫苏叶和桂枝,加入硬质圆底烧瓶,在硬质圆底烧瓶上连接挥发油测定器和回流冷凝管,经回流冷凝,得到药物挥发油;
步骤三:制备中药组合物:取步骤一制备的水提取物和步骤二制备的药物混发油经离心机充分搅拌得到药物混合液,得到中药组合物。
实施例六:一种防治雾霾引起的病症的中药组合物,其剂型为吸入剂,包括以下重量份数的原料组分:4份的桔梗、3份的白前、2份的甘草、3份的陈皮、2份的薄荷、3份的荆芥、0.1份的桑叶和10份的菊花。
一种防治雾霾引起的病症的中药组合物的制备方法,其特征在于,包括以下步骤:
步骤一:水提取物的制备:取白前、桔梗、甘草、桑叶和菊花采用冷浸法或热浸法制备水提取物;
冷浸法包括以下步骤:按上述重量份数称取原料组分,置于锥形瓶中,精密加水,密塞,冷浸,前6个小时内时时振摇,再静置18小时,用干燥滤器迅速滤过得到水提取物;
热浸法包括以下步骤:按上述重量份数称取原料组分,置于锥形瓶中,精密加水,密塞,称定重量,静置1小时后,连接回流冷凝管,加热至沸腾,并保持微沸1小时。放冷后,取下锥形瓶,密塞,再称定重量,用水补足减失的重量,摇匀,用干燥器滤过,精密量取滤液得到水提取物;
步骤二:药物挥发油的制备:取陈皮、荆芥、薄荷,加入硬质圆底烧瓶,在硬质圆底烧瓶上连接挥发油测定器和回流冷凝管,经回流冷凝,得到药物挥发油;
步骤三:制备中药组合物:取步骤一制备的水提取物和步骤二制备的药物混发油经离心机充分搅拌得到药物混合液,得到中药组合物。
实施例七:一种防治雾霾引起的病症的中药组合物,其剂型为吸入剂,包括以下重量份数的原料组分:4份的桔梗、3份的白前、2份的甘草、3份的陈皮、2份的薄荷、3份的荆芥、10份的桑叶、0.1份的菊花、10份的黄芩、0.1份的牛蒡子。
一种防治雾霾引起的病症的中药组合物的制备方法,其特征在于,包括以下步骤:
步骤一:水提取物的制备:取白前、桔梗、甘草、桑叶、菊花、黄岑采用冷浸法或热浸法制备水提取物;
冷浸法包括以下步骤:按上述重量份数称取原料组分,置于锥形瓶中,精密加水,密塞,冷浸,前6个小时内时时振摇,再静置18小时,用干燥滤器迅速滤过得到水提取物;
热浸法包括以下步骤:按上述重量份数称取原料组分,置于锥形瓶中,精密加水,密塞,称定重量,静置1小时后,连接回流冷凝管,加热至沸腾,并保持微沸1小时。放冷后,取下锥形瓶,密塞,再称定重量,用水补足减失的重量,摇匀,用干燥器滤过,精密量取滤液得到水提取物;
步骤二:药物挥发油的制备:取陈皮、荆芥、薄荷、牛蒡子,加入硬质圆底烧瓶,在硬质圆底烧瓶上连接挥发油测定器和回流冷凝管,经回流冷凝,得到药物挥发油;
步骤三:制备中药组合物:取步骤一制备的水提取物和步骤二制备的药物混发油经离心机充分搅拌得到药物混合液,得到中药组合物。
实施例八:一种防治雾霾引起的病症的中药组合物,其剂型为吸入剂,包括以下重量份数的原料组分:4份的桔梗、3份的白前、2份的甘草、3份的陈皮、2份的薄荷、3份的荆芥、0.1份的苍术。
所述中药组合物的剂型为吸入剂,所述吸入剂还包括辅料,所述辅料包括以下重量百分数的原料组分:0.01%的透明质酸、0.5%的银耳多糖、0.1%的三甲基甘氨酸、0.5%的羟乙基纤维和0.01%的对羟基苯甲酸乙酯,余量为无菌蒸馏水。
一种防治雾霾引起的病症的中药组合物的制备方法,其特征在于,包括以下步骤:
步骤一:水提取物的制备:取白前、桔梗和甘草采用冷浸法或热浸法制备水提取物;
冷浸法包括以下步骤:按上述重量份数称取原料组分,置于锥形瓶中,精密加水,密塞,冷浸,前6个小时内时时振摇,再静置18小时,用干燥滤器迅速滤过得到水提取物;
热浸法包括以下步骤:按上述重量份数称取原料组分,置于锥形瓶中,精密加水,密塞,称定重量,静置1小时后,连接回流冷凝管,加热至沸腾,并保持微沸1小时。放冷后,取下锥形瓶,密塞,再称定重量,用水补足减失的重量,摇匀,用干燥器滤过,精密量取滤液得到水提取物;
步骤二:药物挥发油的制备:取陈皮、荆芥、薄荷、苍术,加入硬质圆底烧瓶,在硬质圆底烧瓶上连接挥发油测定器和回流冷凝管,经回流冷凝,得到药物挥发油;
步骤三:制备中药组合物:取步骤一制备的水提取物和步骤二制备的药物混发油经离心机充分搅拌得到药物混合液,得到中药组合物。
步骤四:制备吸入剂:按上述重量百分数称取辅料各原料成分与上述步骤制备的中药组合物混合均匀,滴于载体上得到吸附剂。所述辅料与中药组合物的重量比与现有技术中吸附剂的有效成分与辅料的重量比相同,本领域技术人员基于现有技术和本发明公开内容能够直接得到。
实施例九:一种防治雾霾引起的病症的中药组合物,其剂型为吸入剂,包括以下重量份数的原料组分:4份的桔梗、3份的白前、2份的甘草、3份的陈皮、2份的薄荷、3份的荆芥、10份的苍术、0.1份的半夏和10份的草果。
所述中药组合物的剂型为吸入剂,所述吸入剂还包括辅料,所述辅料包括以下重量百分数的原料组分:0.5%的透明质酸、0.01%的银耳多糖、1%的三甲基甘氨酸、0.01%的羟乙基纤维和0.5%的对羟基苯甲酸乙酯,余量为无菌蒸馏水。
一种防治雾霾引起的病症的中药组合物的制备方法,其特征在于,包括以下步骤:
步骤一:水提取物的制备:取白前、桔梗和甘草采用冷浸法或热浸法制备水提取物;
冷浸法包括以下步骤:按上述重量份数称取原料组分,置于锥形瓶中,精密加水,密塞,冷浸,前6个小时内时时振摇,再静置18小时,用干燥滤器迅速滤过得到水提取物;
热浸法包括以下步骤:按上述重量份数称取原料组分,置于锥形瓶中,精密加水,密塞,称定重量,静置1小时后,连接回流冷凝管,加热至沸腾,并保持微沸1小时。放冷后,取下锥形瓶,密塞,再称定重量,用水补足减失的重量,摇匀,用干燥器滤过,精密量取滤液得到水提取物;
步骤二:药物挥发油的制备:取陈皮、荆芥、薄荷、苍术、半夏和草果,加入硬质圆底烧瓶,在硬质圆底烧瓶上连接挥发油测定器和回流冷凝管,经回流冷凝,得到药物挥发油;
步骤三:制备中药组合物:取步骤一制备的水提取物和步骤二制备的药物混发油经离心机充分搅拌得到药物混合液,得到中药组合物。
步骤四:制备吸入剂:按上述重量百分数称取辅料各原料成分与上述步骤制备的中药组合物混合均匀,滴于载体上得到吸附剂。所述辅料与中药组合物的重量比与现有技术中吸附剂的有效成分与辅料的重量比相同,本领域技术人员基于现有技术和本发明公开内容能够直接得到。
实施例十:一种防治雾霾引起的病症的中药组合物,其剂型为吸入剂,包括以下重量份数的原料组分:4份的桔梗、3份的白前、2份的甘草、3份的陈皮、2份的薄荷、3份的荆芥、0.5份的紫苏叶、2份的炙麻黄、0.1份的干姜、10份的桂枝、5份的桑叶、3份的菊花、0.1份的黄芩、10份的牛蒡子、1份的苍术、10份的半夏和0.1份的草果。
所述中药组合物的剂型为吸入剂,所述吸入剂还包括辅料,所述辅料包括以下重量百分数的原料组分:0.1%的透明质酸和/或0.5%的银耳多糖,余量为无菌蒸馏水。
一种防治雾霾引起的病症的中药组合物的制备方法,其特征在于,包括以下步骤:
步骤一:水提取物的制备:取白前、桔梗、甘草、炙麻黄、干姜、桑叶、菊花和黄芩采用冷浸法或热浸法制备水提取物;
冷浸法包括以下步骤:按上述重量份数称取原料组分,置于锥形瓶中,精密加水,密塞,冷浸,前6个小时内时时振摇,再静置18小时,用干燥滤器迅速滤过得到水提取物;
热浸法包括以下步骤:按上述重量份数称取原料组分,置于锥形瓶中,精密加水,密塞,称定重量,静置1小时后,连接回流冷凝管,加热至沸腾,并保持微沸1小时。放冷后,取下锥形瓶,密塞,再称定重量,用水补足减失的重量,摇匀,用干燥器滤过,精密量取滤液得到水提取物;
步骤二:药物挥发油的制备:取陈皮、荆芥、薄荷、紫苏叶、桂枝、牛蒡子、苍术、半夏和草果,加入硬质圆底烧瓶,在硬质圆底烧瓶上连接挥发油测定器和回流冷凝管,经回流冷凝,得到药物挥发油;
步骤三:制备中药组合物:取步骤一制备的水提取物和步骤二制备的药物混发油经离心机充分搅拌得到药物混合液,得到中药组合物。
步骤四:制备吸入剂:按上述重量百分数称取辅料各原料成分与上述步骤制备的中药组合物混合均匀,滴于载体上得到吸附剂。所述辅料与中药组合物的重量比与现有技术中吸附剂的有效成分与辅料的重量比相同,本领域技术人员基于现有技术和本发明公开内容能够直接得到。
实施例一至实施例十临床药理实验:
临床药理实验:
通过招募志愿者,经过筛选,将各实施例得到的中药组合物作为试验组,放置于口罩中进行体验并完成效果评估量表,同时以申请公布号为CN103238954A的发明专利公开了一种雾霾天气发生时保护人们呼吸道肺部免遭伤害的中药口罩作为对照组一,以市售防雾霾口罩作为对照组二完成效果评估量表,结果见表1。
确定口罩的有效性、可行性。
随机选取240名受试者,分成12组,分别佩戴试验组一至十、对照组一和对照组二口罩1个/天,共3天,填写评估量表,以统计口罩的有效程度及有效率。
受试者纳入标准:
(1)非感染性咳嗽。
(2)有明显天气因素引发,即在雾霾天气时发生的咳嗽。
(3)上呼吸道症状明显。例如:咽干、咽痒、咽喉异物感,刺激性咳嗽。
受试者排除标准:
(1)伴有高血压、心血管疾病及甲状腺功能亢进症、贫血等疾病者。
(2)伴有其他重要脏器器质性病变者。
(3)已确诊为已知呼吸系统疾病患者。
(4)使用口罩已服用药物治疗不适症状。
(5)孕妇、哺乳期妇女。
(7)年龄≥50岁或≤15岁者。
针对各评分项目评分标准:分数(满分5分),1分最差,5分最优。
表1临床实验结果
由表一数据可知,本发明实施例一至实施例十所述的中药组合物在用于制备口罩时的体验效果更佳,远远优于对照组一和对照组二。同时实施例三和实施例十为本发明的优选实施例。
实施例十一:一种含有中药组合物的口罩,所述的中药组合物为上述的治雾霾引起的病症的中药组合物。将所述中药组合物按照实施例7至实施例9任一项所述的方法制备成吸附剂,并将所述吸附剂滴于插片载体上,将载体超乳口罩口鼻处,即得到一种含有中药组合物的口罩。
优选地,所述口罩为加湿口罩
肺组织病理学检测试验:
1.1实验动物及分组
采用上海斯莱克实验动物有限责任公司(许可证号码SCXK(沪)2012-0002)提供的6周龄健康雄性Wistar大鼠48只,体重166g~205g。大鼠适应性饲养1周后,随机平均分为6组。
1.2主要实验仪器
TH-150C型智能中流量空气总悬浮微粒采样器,配PM10-PM5-PM2.5组合式多功能切割器(武汉市天虹仪表有限责任公司),SB25-12D超声波振荡器(宁波新芝生物科技股份有限公司),LABCONCO冷冻干燥机(美国),DM750病理显微镜(Leica),FC500流式细胞仪(美国Beckman Coulter)。
1.3主要试剂
LDH,ACP,AKP试剂盒(上海易利生物科技有限公司);磷酸盐缓冲液(PBS,pH为7.2~7.4);红细胞裂解液(pH为7.2~7.4),4℃保存备用。
1.4PM2.5的采集与制备
样品采自北京市朝阳区三环路边,采样时间为冬春季节,雨天不采样,实际采样30d,每天连续采样10h,采样期间PM2.5日平均质量浓度为151μg/m3,达中度污染水平。PM2.5悬液的制备:将载有颗粒物的滤膜裁剪成1cm×3cm大小,浸入50mL双蒸水中。超声处理30min×3次,洗脱颗粒物,6层纱布过滤。滤液于4℃,12 000r/min离心30min。收集下层悬液,分装于小玻瓶中,于-80℃过夜。次日取出样品,进行真空冷冻干燥,实验时用生理盐水配制成相应质量浓度的PM2.5悬液。
1.5动物处理
1.5.1分组:依次取实施例一、实施例三和实施例十所得到的中药组合物作为实验组分别针对3组大鼠依次给药,给药量为每Kg体重给药1g生药,取申请公布号为CN103127369 A的发明专利公开的一种治疗呼吸道雾霾侵害的中药组合物及其制备方法所述的中药组合物作为阳性对照组对1组大鼠进行给药,该中药组合物包括下列重量份数的原料药:桔梗10-30克、浙贝母1-15克、罗汉果1-15克、甘草1-15克、沙参1-10克。给药量为每Kg体重给药1g生药;取1组大鼠作为空白对照组,同时取1组大鼠作为PM2.5染毒组;
动物染毒:染尘方式采用非暴露式气管滴注染毒法。在给药60min后,实验动物乙醚麻醉后固定于染尘架上,将气管导管通过声门裂,注入预热的PM2.5悬液,10s后将动物侧卧位放置于保温饲养笼内。每天气管滴注1次,滴注量为1mL/kg体重,连续染毒3d,每次间隔24h。空白对照组不做处理,pm2.5染毒组、实验组和阳性对照组均染毒处理。
1.5.2支气管肺泡灌洗液(BALF)的制备最后一次染毒结束24h后,用10%水合氯醛麻醉大鼠。打开腹腔,腹主动脉放血处死,将肺灌洗针头插入分离出的气管,结扎固定,并以止血钳夹闭左主支气管,用冷PBS灌洗肺部,得到支气管肺泡灌洗液(BALF),经4℃,1 200r/min离心10min,分装上清,-80℃保存待测。
1.5.3肺单细胞悬液的制备
大鼠处死后,剪取部分未经灌洗的左肺,在平皿中轻刮组织块,并以PBS冲洗;用吸管吸取组织匀浆,用200目筛网过滤到试管内,滤液经800r/min离心5min后弃上清,加入红细胞裂解液2mL孵育10min,离心去上清;再用PBS漂洗3次,加2mL PBS得到大鼠肺单细胞悬液。
1.6肺灌洗液中部分酶、细胞因子的测定
采用标准比色法测定支气管肺泡灌洗液中乳酸脱氢酶(LDH)、酸性磷酸酶(ACP)、碱性磷酸酶(AKP)含量。
1.7肺组织病理学检查
取部分左肺,用10%的中性甲醛固定,制成石蜡切片,苏木素/伊红染色,观察肺组织病理学改变。
1.8数据处理和统计方法
实验数据均以均数±标准差(x±s)表示。用SAS 9.0软件包,采用单因素方差分析对实验数据进行分析,P<0.05时表示差异具有统计学意义。
2结果
1.PM2.5染毒后大鼠肺组织病理学改变
空白对照组可见肺泡大小相对一致,内壁光滑,肺泡壁呈单层。与空白对照组相比,PM2.5染毒组部分肺泡及支气管组织内可见明显异物颗粒,肺间质明显增宽;肺泡腔及肺间质内红细胞明显增多。实验组与PM2.5染毒组相比,异物颗粒显著减少率100%,肺泡壁完整性破坏率减少67.5%;实验组与阳性对照组相比,异物颗粒显著减少率30%,肺泡壁完整性破坏率减少25.4%。与空白对照组相比,实验组和阳性对照组均可见异物颗粒,但较PM2.5染毒组相比,实验组颗粒密度减小率为75%。与空白对照组相比,实验组组肺泡腔及肺间质内红细胞明显增多,但较PM2.5染毒组相比,单位面积红细胞减小率为87.5%。与空白对照组相比,实验组、阳性对照组和PM2.5染毒组肺泡内壁均略有粗糙和增厚,肺泡排列紊乱,其中实验组的肺泡较阳性对照组和PM2.5染毒组状况均好。
2、PM2.5对大鼠气管组织的影响:
空白对照组气管黏膜表面纤毛密集,分布均匀,呈密密的绒毯状。实验组可见气管黏膜表面被覆少量黏液,可见少量杯状细胞,气管黏膜表面纤毛密集,偶见纤毛粘连,排列紊乱,其间可见散在杯状细胞。阳性对照组可见气管黏膜表面被覆中量黏液,、气管黏膜表面纤毛密集,偶见纤毛粘连,排列紊乱。PM2.5染毒组可见气管黏膜表面可见黏液被覆,相比于实验组明显增多。纤毛密集,排列紊乱。纤毛粘连倒伏,偶见断裂。大鼠气管组织细胞损伤程度由严重至较轻顺序依次为PM2.5染毒组、阳性对照组、实验组、空白对照组。
3、PM2.5染毒后大鼠肺泡灌洗液中部分酶、细胞因子水平的变化、肺灌洗液中ACP,AKP和LDH含量的变化。
PM2.5染毒组大鼠肺泡灌洗液中AKP显著低于对照组,六组AKP高低排序:空白对照组>实施例十>实施例三>实施例一>阳性对照组>PM2.5染毒组。PM2.5染毒组、实验组组和阳性对照组的ACP,LDH含量与对照组比较差异均无统计学意义。数据如表2所示:
表2大鼠肺泡灌洗液中ACP,AKP和LDH含量
组别 | ACP/(IU/L) | AKP/(IU/L) | LDH/(IU/L) |
空白对照组 | 3.331±0.598 | 74.793±10.910 | 421.687±26.952 |
实施例一 | 3.296±0.545 | 55.963±10.628* | 410.896±25.214 |
实施例三 | 3.252±0.515 | 55.782±10.521* | 410.589±25.351 |
实施例十 | 3.265±0.531 | 55.572±10.603* | 410.492±25.241 |
阳性对照组 | 3.121±0.511 | 59.426±10.026* | 428.286±25.398 |
PM2.5染毒组 | 3.007±0.512 | 61.319±10.021* | 440.874±25.821 |
注:*与对照组比较P<0.05
讨论:
本实验大鼠肺泡灌洗液中酶ACP、LDH水平均无明显变化;仅实验组、PM2.5染毒组和阳性对照组的大鼠肺泡灌洗液中AKP显著低于对照组。AKP主要由肺泡II型细胞产生,部分由中性粒细胞产生,其活性提示了肺泡II型细胞受损程度和中性粒细胞浸润程度,AKP降低与肺泡II型细胞的增生作用有关。由此可得出结论,实验组对AKP的影响优于PM2.5染毒组和阳性对照组。与空白对照组相比,实验组与PM 2.5染毒组和阳性对照组AKP降低具有统计学意义。
以上所述仅为本发明的优选实施例而已,并不用于限制本发明,对于本领域的技术人员来说,本发明可以有各种更改和变化。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (10)
1.一种防治雾霾引起的病症的中药组合物,其特征在于,包括以下重量份数的原料组分:1~30份的桔梗、0.5~15份的白前、0.1~10份的甘草、0.5~15份的陈皮、0.1~10份的薄荷和0.5~15份的荆芥。
2.根据权利要求1所述的防治雾霾引起的病症的中药组合物,其特征在于,包括以下重量份数的原料组分:2~8份的桔梗、1~5份的白前、1~5份的甘草、1~5份的陈皮、1~4份的薄荷和1~5份的荆芥。
3.根据权利要求1所述的防治雾霾引起的病症的中药组合物,其特征在于,还包括以下重量份数的原料组分:重量份数为0.1~10份的紫苏叶、0.1~10份的炙麻黄、0.1~10份的干姜、0.1~10份的桂枝、0.1~10份的桑叶、0.1~10份的菊花、0.1~10份的黄芩、0.1~10份的牛蒡子、0.1~10份的苍术、0.1~10份的半夏和0.1~10份的草果中的一种或几种。
4.根据权利要求1~3任一项所述的防治雾霾引起的病症的中药组合物,其特征在于,所述的中药组合物的剂型为吸入剂,所述吸入剂还包括辅料。
5.根据权利要求4所述的防治雾霾引起的病症的中药组合物,其特征在于,所述辅料包括以下重量百分数的原料组分:0.01~0.5%的透明质酸、0.01~0.5%的银耳多糖、0.1~1%的三甲基甘氨酸、0.01~0.5%的羟乙基纤维和0.01~0.5%的对羟基苯甲酸乙酯中的一种或几种,余量为无菌蒸馏水。
6.一种权利要求1~5任一项所述的防治雾霾引起的病症的中药组合物的制备方法,其特征在于,包括以下步骤:
步骤一:水提取物的制备:取白前、桔梗和甘草采用冷浸法或热浸法制备水提取物;
步骤二:药物挥发油的制备:取陈皮、荆芥和薄荷,采用蒸馏萃取方法得到相应的药物挥发油;
步骤三:制备中药组合物:取步骤一制备的水提取物和步骤二制备的药物混发油经离心机充分搅拌得到药物混合液,得到中药组合物。
7.根据权利要求6所述的防治雾霾引起的病症的中药组合物的制备方法,其特征在于,所述步骤一中水提取物的原料还包括炙麻黄、干姜、桑叶、菊花和黄芩中的一种以上。
8.根据权利要求6所述的防治雾霾引起的病症的中药组合物的制备方法,其特征在于,所述步骤二药物挥发油的原料还包括紫苏叶、桂枝、牛蒡子、苍术、半夏和草果中的一种以上。
9.根据权利要求6所述的防治雾霾引起的病症的中药组合物的制备方法,其特征在于,所述的中药组合物的剂型为吸入剂,所述吸入剂还包括辅料,取制备的中药组合物与辅料混合均匀,所述辅料包括以下重量百分数的原料组分:0.01~0.5%的透明质酸、0.01~0.5%的银耳多糖、0.1~1%的三甲基甘氨酸、0.01~0.5%的羟乙基纤维和0.01~0.5%的对羟基苯甲酸乙酯中的一种或几种,余量为无菌蒸馏水。
10.一种含有中药组合物的口罩,其特征在于,所述的中药组合物为权利要求1~5任一项所述的防治雾霾引起的病症的中药组合物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610891372.7A CN106421039A (zh) | 2016-10-12 | 2016-10-12 | 一种防治雾霾引起的病症的中药组合物、其制备方法和含其的口罩 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610891372.7A CN106421039A (zh) | 2016-10-12 | 2016-10-12 | 一种防治雾霾引起的病症的中药组合物、其制备方法和含其的口罩 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106421039A true CN106421039A (zh) | 2017-02-22 |
Family
ID=58173732
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610891372.7A Pending CN106421039A (zh) | 2016-10-12 | 2016-10-12 | 一种防治雾霾引起的病症的中药组合物、其制备方法和含其的口罩 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106421039A (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106880716A (zh) * | 2017-03-03 | 2017-06-23 | 夏钦珠 | 抗霾益肺药物组合物及其制备方法 |
CN107029139A (zh) * | 2017-05-23 | 2017-08-11 | 贵阳中医学院 | 一种清痰润肺的中药组合物、制剂及其制备方法 |
CN109420028A (zh) * | 2017-08-21 | 2019-03-05 | 孙辅 | 一种防治雾霾的药物 |
CN109758473A (zh) * | 2019-03-26 | 2019-05-17 | 广东省微生物研究所(广东省微生物分析检测中心) | 一种银耳多糖提取物在制备治疗干眼症的药物中的用途 |
CN110742339A (zh) * | 2019-10-30 | 2020-02-04 | 山东省中医药研究院 | 一种抗呼吸道合胞病毒口罩及其制备方法 |
CN111888413A (zh) * | 2020-09-18 | 2020-11-06 | 天津中医药大学 | 一种用于秋季呼吸道疾病的药物组合物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101138591A (zh) * | 2007-08-25 | 2008-03-12 | 尹克华 | 治疗外感咳嗽的中药 |
CN103238954A (zh) * | 2013-05-23 | 2013-08-14 | 天津开发区经经新优技术产品开发有限公司 | 雾霾天气发生时保护人们呼吸道肺部免遭伤害的中药口罩 |
-
2016
- 2016-10-12 CN CN201610891372.7A patent/CN106421039A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101138591A (zh) * | 2007-08-25 | 2008-03-12 | 尹克华 | 治疗外感咳嗽的中药 |
CN103238954A (zh) * | 2013-05-23 | 2013-08-14 | 天津开发区经经新优技术产品开发有限公司 | 雾霾天气发生时保护人们呼吸道肺部免遭伤害的中药口罩 |
Non-Patent Citations (1)
Title |
---|
刘强、刘莉: "《中药新产品开发》", 31 March 2013, 中国医药科技出版社 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106880716A (zh) * | 2017-03-03 | 2017-06-23 | 夏钦珠 | 抗霾益肺药物组合物及其制备方法 |
CN107029139A (zh) * | 2017-05-23 | 2017-08-11 | 贵阳中医学院 | 一种清痰润肺的中药组合物、制剂及其制备方法 |
CN107029139B (zh) * | 2017-05-23 | 2020-12-29 | 贵阳中医学院 | 一种清痰润肺的中药组合物、制剂及其制备方法 |
CN109420028A (zh) * | 2017-08-21 | 2019-03-05 | 孙辅 | 一种防治雾霾的药物 |
CN109758473A (zh) * | 2019-03-26 | 2019-05-17 | 广东省微生物研究所(广东省微生物分析检测中心) | 一种银耳多糖提取物在制备治疗干眼症的药物中的用途 |
CN110742339A (zh) * | 2019-10-30 | 2020-02-04 | 山东省中医药研究院 | 一种抗呼吸道合胞病毒口罩及其制备方法 |
CN111888413A (zh) * | 2020-09-18 | 2020-11-06 | 天津中医药大学 | 一种用于秋季呼吸道疾病的药物组合物 |
CN111888413B (zh) * | 2020-09-18 | 2022-07-12 | 天津中医药大学 | 一种用于秋季呼吸道疾病的药物组合物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106421039A (zh) | 一种防治雾霾引起的病症的中药组合物、其制备方法和含其的口罩 | |
CN1947754B (zh) | 一种治疗小儿哮喘的药物及其制备方法 | |
CN103127369A (zh) | 一种治疗呼吸道雾霾侵害的中药组合物及其制备方法 | |
CN111280526A (zh) | 用于预防流感病毒和/或新型冠状病毒引起的肺炎的口罩及其制备方法 | |
CN102696928B (zh) | 用于治疗猪流感的饲料、中药组合物、制备方法和应用 | |
CN118021929A (zh) | 一种治疗咳嗽的药物组合物及其制备方法 | |
CN107648446A (zh) | 一种治疗外感咳嗽的中药配方及其制备方法 | |
CN1682895A (zh) | 一种定喘止咳的药物及其制备方法 | |
CN105535738A (zh) | 一种用于治疗慢性咳嗽的中药制剂及其制备方法 | |
CN103494927B (zh) | 一种用于治疗鸡呼吸道疾病的中药组合物及其制备方法 | |
CN104800382A (zh) | 一种用于治疗感冒的中药组合物及其制备方法和应用 | |
CN116139237B (zh) | 一种防治新型冠状病毒等所致呼吸道感染的中药组合物及其应用 | |
CN103316086A (zh) | 一种治疗流行性感冒的藏药及其制备方法 | |
CN105497723A (zh) | 一种治疗细菌性肺炎的中药制剂及其制备方法 | |
CN105412281A (zh) | 一种治疗过敏性哮喘的中药组合物及其制备方法 | |
CN105250385A (zh) | 一种治疗婴幼儿鼻塞的滴鼻剂 | |
CN102526236B (zh) | 一种治疗流行性感冒的药物及其制备方法 | |
CN100386110C (zh) | 一种治疗气管炎的中草药膏 | |
WO2023024632A1 (zh) | 一种治疗过敏性鼻炎的药物组合物及其制备方法 | |
CN105998725A (zh) | 用于治疗矽肺的中药制剂 | |
CN1410105A (zh) | 紫贝止咳颗粒及制备方法 | |
CN111888452A (zh) | 一种杏茯甘草组合物及其制备方法和应用 | |
CN102626511B (zh) | 一种用于止咳祛痰的药物组合物 | |
CN104225405A (zh) | 一种治疗呼吸道感染的中药含片及制备方法 | |
CN103784712A (zh) | 一种能够修复由于环境污染导致肺部损伤的保健品及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170222 |